Salud financiera de hoja de balance de Huakang Biomedical Holdings

Salud financiera controles de criterios 5/6

Huakang Biomedical Holdings tiene un patrimonio de los accionistas total de CN¥56.5M y una deuda total de CN¥2.9M, lo que sitúa su ratio deuda-patrimonio en 5.1%. Sus activos y pasivos totales son CN¥66.8M y CN¥10.3M respectivamente.

Información clave

5.1%

Ratio deuda-patrimonio

CN¥2.88m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CN¥36.66m
Patrimonio	CN¥56.50m
Total pasivo	CN¥10.29m
Activos totales	CN¥66.79m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥56.3M) de 8622 superan a sus pasivos a corto plazo (CN¥9.7M).

Pasivo a largo plazo: Los activos a corto plazo de 8622 (CN¥56.3M) superan a sus pasivos a largo plazo (CN¥611.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 8622 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 8622 ha crecido de 0% a 5.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 8622 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 8622 tiene suficiente cash runway para más de 3 años si el flujo de caja libre sigue creciendo a tasas históricas de 23.8% cada año

Salud financiera de hoja de balance de Huakang Biomedical Holdings

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera